Market Summary
USD204.02+0.56
Market Closed0.28%
TFX Stock Price
TFX RSI Chart
TFX Valuation
TFX Price/Sales (Trailing)
TFX Profitability
TFX Fundamentals
TFX Revenue
TFX Earnings
Price Action
52 Week Range
182.37276.43
(Low)(High)
Last 7 days
-4.4%
Last 30 days
-6.2%
Last 90 days
-14.0%
Trailing 12 Months
-3.6%
TFX Financial Health
TFX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TFX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-09 | Kelly Liam | gifted | - | - | 5,768 | chairman, president & ceo |
2023-08-09 | Kelly Liam | gifted | - | - | -5,768 | chairman, president & ceo |
2023-05-10 | RANDLE STUART A | sold | -742,290 | 245 | -3,021 | - |
2023-05-10 | RANDLE STUART A | acquired | 305,484 | 101 | 3,021 | - |
2023-05-09 | Klasko Stephen K. M.D. | acquired | - | - | 681 | - |
2023-05-09 | RANDLE STUART A | acquired | - | - | 527 | - |
2023-05-09 | Patil Neena M | acquired | - | - | 527 | - |
2023-05-09 | Krakauer Andrew A | acquired | - | - | 527 | - |
2023-05-09 | HEINMILLER JOHN C | acquired | - | - | 527 | - |
2023-05-09 | HAGGERTY GRETCHEN R | acquired | - | - | 527 | - |
Which funds bought or sold TFX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 89.52 | 8,543,000 | 19,082,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | added | 43.48 | 2,161 | 7,987 | -% |
2023-08-30 | Western Wealth Management, LLC | added | 15.72 | 38,976 | 406,235 | 0.04% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | -249 | 2,493 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -13,536 | 290,436 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 7.7 | 36,356 | 1,281,300 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -75.99 | -3,422,000 | 1,019,000 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.19 | -1,275,470 | 18,214,500 | 0.03% |
2023-08-21 | BOKF, NA | added | 3.12 | -4,673 | 312,218 | 0.01% |
2023-08-17 | Coppell Advisory Solutions LLC | new | - | 1,410 | 1,410 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Teleflex
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 18.4% | 8,633,473 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 11.56% | 5,420,563 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 6.59% | 3,092,719 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.5% | 3,969,361 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 13.8% | 6,494,778 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 10.81% | 5,063,204 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 7.11% | 3,331,136 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 10.4% | 4,856,339 | SC 13G/A | |
| Jan 25, 2022 | blackrock inc. | 10.4% | 4,856,339 | SC 13G/A | |
| Sep 10, 2021 | price t rowe associates inc /md/ | 15.6% | 7,305,896 | SC 13G/A |
Recent SEC filings of Teleflex
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 31, 2023 | 8-K | Current Report | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Jun 26, 2023 | 11-K | Employee Benefit Details |
TFX Fair Value
Loading...
Peers (Alternatives to Teleflex)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.3B | 19.5B | 3.38% | 36.58% | 39.99 | 5.57 | 10.36% | 30.30% |
ISRG | 101.2B | 6.7B | -0.75% | 50.83% | 71.05 | 15.19 | 11.75% | -0.66% |
BSX | 77.5B | 13.4B | 6.45% | 36.39% | 85 | 5.78 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -4.29% | 12.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.3B | 5.7B | -8.22% | -17.24% | 30.48 | 7.49 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.65 | 10.11 | 16.30% | 250.21% |
SWAV | 7.1B | 616.6M | -12.54% | -24.86% | 29.24 | 11.56 | 69.52% | 343.68% |
GMED | 5.1B | 1.1B | -6.10% | -12.07% | 24.23 | 4.65 | 12.63% | 50.85% |
IRTC | 2.6B | 452.1M | -21.20% | -33.94% | -26.32 | 5.78 | 24.99% | 24.09% |
TNDM | 1.3B | 790.3M | -27.09% | -56.49% | -5.97 | 1.69 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -15.15% | 56.11% | -9.32 | 3.69 | 44.49% | -2.43% |
AVNS | 947.4M | 780.7M | -7.75% | -9.65% | -26.32 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 609.7M | 162.9M | -27.67% | -61.65% | -11.53 | 3.74 | 42.67% | 12.82% |
Teleflex News
Returns for TFX
Cumulative Returns on TFX
10.3%
10-Year Cumulative Returns
3.0%
7-Year Cumulative Returns
-5.1%
5-Year Cumulative Returns
-14.7%
3-Year Cumulative Returns
Risks for TFX
What is the probability of a big loss on TFX?
57.3%
Probability that Teleflex stock will be more than 20% underwater in next one year
48.5%
Probability that Teleflex stock will be more than 30% underwater in next one year.
13.8%
Probability that Teleflex stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TFX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Teleflex was unfortunately bought at previous high price.
Drawdowns
Financials for Teleflex
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.4% | 2,899 | 2,860 | 2,791 | 2,795 | 2,808 | 2,817 | 2,810 | 2,759 | 2,687 | 2,540 | 2,537 | 2,507 | 2,527 | 2,612 | 2,595 | 2,556 | 2,517 | 2,475 | 2,448 | 2,402 | 2,327 |
| Gross Profit | 1.2% | 1,595 | 1,576 | 1,531 | 1,529 | 1,543 | 1,551 | 1,550 | 1,513 | 1,455 | 1,336 | 1,325 | 1,319 | 1,345 | 1,419 | 1,409 | 1,397 | 1,385 | 1,377 | 1,384 | 1,349 | 1,302 |
| S&GA Expenses | 0.7% | 899 | 893 | 864 | 858 | 854 | 861 | 860 | 865 | 832 | 799 | 744 | 731 | 768 | 793 | 852 | 769 | 774 | 789 | 797 | 873 | 822 |
| R&D Expenses | 1.6% | 161 | 159 | 154 | 147 | 141 | 137 | 131 | 129 | 126 | 122 | 120 | 117 | 116 | 114 | 114 | 111 | 109 | 107 | 106 | 104 | 99.00 |
| EBITDA | -100.0% | - | 580 | 567 | 594 | 705 | 853 | 854 | 786 | 676 | 598 | 651 | 791 | 738 | 766 | 639 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.20* | 0.20* | 0.21* | 0.25* | 0.30* | 0.30* | 0.28* | 0.25* | 0.24* | 0.26* | 0.32* | 0.29* | 0.29* | 0.25* | - | - | - | - | - | - |
| Interest Expenses | 10.2% | 69.00 | 62.00 | 54.00 | 47.00 | 46.00 | 51.00 | 57.00 | 64.00 | 68.00 | 68.00 | 66.00 | 65.00 | 68.00 | 73.00 | 80.00 | 86.00 | 94.00 | 100 | 103 | 103 | 98.00 |
| Earnings Before Taxes | 0.7% | 453 | 450 | 446 | 480 | 590 | 566 | 559 | 493 | 379 | 303 | 358 | 382 | 365 | 429 | 340 | 335 | 291 | 211 | 220 | 191 | 225 |
| EBT Margin | -100.0% | - | 0.16* | 0.16* | 0.17* | 0.21* | 0.20* | 0.20* | 0.18* | 0.14* | 0.12* | 0.14* | 0.15* | 0.14* | 0.16* | 0.13* | - | - | - | - | - | - |
| Net Income | 1.6% | 369 | 363 | 363 | 413 | 510 | 488 | 485 | 433 | 351 | 279 | 335 | 367 | 480 | 552 | 461 | 444 | 271 | 186 | 201 | 68.00 | 88.00 |
| Net Income Margin | -100.0% | - | 0.13* | 0.13* | 0.15* | 0.18* | 0.17* | 0.17* | 0.16* | 0.13* | 0.11* | 0.13* | 0.15* | 0.19* | 0.21* | 0.18* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 277 | 264 | 374 | 422 | 538 | 581 | 566 | 480 | 469 | 346 | 308 | 328 | 267 | 334 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.3% | 6,896 | 6,918 | 6,928 | 6,758 | 6,732 | 6,873 | 6,872 | 7,040 | 7,066 | 7,028 | 7,153 | 6,613 | 6,765 | 6,702 | 6,310 | 6,257 | 6,314 | 6,268 | 6,278 | 6,201 | 6,175 |
| Current Assets | 1.2% | 1,446 | 1,428 | 1,411 | 1,459 | 1,385 | 1,494 | 1,429 | 1,542 | 1,437 | 1,379 | 1,422 | 1,421 | 1,545 | 1,447 | 1,306 | 1,238 | 1,245 | 1,183 | 1,236 | 1,241 | 1,185 |
| Cash Equivalents | -5.0% | 251 | 264 | 292 | 397 | 308 | 467 | 445 | 481 | 362 | 325 | 376 | 347 | 554 | 406 | 301 | 258 | 304 | 271 | 357 | 356 | 346 |
| Inventory | 2.8% | 632 | 614 | 579 | 530 | 511 | 491 | 478 | 484 | 490 | 512 | 513 | 526 | 515 | 489 | 477 | 473 | 461 | 446 | 428 | 411 | 405 |
| Net PPE | 1.3% | 465 | 459 | 447 | 422 | 429 | 436 | 444 | 446 | 450 | 468 | 474 | 445 | 432 | 427 | 431 | 430 | 425 | 410 | 433 | 421 | 411 |
| Goodwill | -0.1% | 2,546 | 2,548 | 2,537 | 71.00 | 2,461 | 2,493 | 2,504 | 2,523 | 2,537 | 2,566 | 2,586 | 2,364 | 2,344 | 2,332 | 2,245 | 2,231 | 2,250 | 2,248 | 2,247 | 30.00 | 2,221 |
| Liabilities | -4.5% | 2,681 | 2,808 | 2,906 | 2,863 | 2,879 | 3,078 | 3,117 | 3,382 | 3,600 | 3,652 | 3,816 | 3,377 | 3,668 | 3,629 | 3,331 | 3,404 | 3,650 | 3,698 | 3,738 | 3,694 | 3,741 |
| Current Liabilities | -3.5% | 555 | 576 | 581 | 611 | 610 | 656 | 680 | 562 | 527 | 508 | 540 | 475 | 457 | 402 | 563 | 530 | 494 | 521 | 582 | 549 | 536 |
| LT Debt, Non Current | -5.1% | 1,471 | 1,549 | 1,624 | 1,594 | 1,606 | 1,741 | 1,740 | 1,949 | 2,216 | 2,295 | 2,378 | 2,036 | 2,329 | 2,341 | 1,859 | 1,949 | 2,081 | 2,073 | 2,072 | 2,076 | 2,145 |
| Shareholder's Equity | 2.6% | 4,215 | 4,110 | 4,022 | 3,895 | 3,853 | 3,796 | 3,755 | 3,658 | 3,466 | 3,376 | 3,336 | 3,236 | 3,097 | 3,073 | 2,979 | 2,853 | 2,665 | 2,570 | 2,540 | 2,507 | 2,434 |
| Retained Earnings | - | - | - | 3,817 | - | - | - | 3,518 | - | - | - | 3,096 | - | - | - | 2,825 | - | - | - | 2,428 | - | - |
| Additional Paid-In Capital | - | - | - | 715 | - | - | - | 693 | - | - | - | 652 | - | - | - | 617 | - | - | - | 575 | - | - |
| Shares Outstanding | 0.1% | 47.00 | 47.00 | - | 47.00 | 47.00 | 47.00 | - | 47.00 | 47.00 | 47.00 | - | 47.00 | 46.00 | 46.00 | - | 46.00 | 46.00 | 46.00 | - | 46.00 | 46.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 12.7% | 412 | 365 | 343 | 446 | 489 | 603 | 652 | 646 | 568 | 559 | 437 | 389 | 414 | 365 | 437 | 421 | 411 | 408 | 435 | 410 | 410 |
| Share Based Compensation | -1.7% | 28.00 | 29.00 | 27.00 | 26.00 | 24.00 | 23.00 | 23.00 | 23.00 | 24.00 | 23.00 | 21.00 | 22.00 | 23.00 | 25.00 | 27.00 | 26.00 | 24.00 | 23.00 | 22.00 | 21.00 | 21.00 |
| Cashflow From Investing | 9.1% | -244 | -268 | -259 | -68.20 | 144 | 165 | 157 | -351 | -574 | -574 | -837 | -318 | -320 | -334 | -73.48 | -191 | -183 | -200 | -196 | -852 | -869 |
| Cashflow From Financing | 21.2% | -228 | -290 | -217 | -415 | -649 | -605 | -715 | -161 | -197 | -81.66 | 455 | 8.00 | 161 | 111 | -418 | -317 | -271 | -298 | -206 | -213 | 121 |
| Dividend Payments | 0.0% | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 64.00 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 63.00 | 62.00 | 62.00 | 62.00 | 62.00 |
TFX Income Statement
2023-07-02CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jul. 02, 2023 | Jun. 26, 2022 | Jul. 02, 2023 | Jun. 26, 2022 | |
| Income Statement [Abstract] | ||||
| Net revenues | $ 743,259 | $ 704,542 | $ 1,454,191 | $ 1,346,257 |
| Cost of goods sold | 335,436 | 315,709 | 654,988 | 611,191 |
| Gross profit | 407,823 | 388,833 | 799,203 | 735,066 |
| Selling, general and administrative expenses | 223,306 | 216,825 | 456,022 | 420,757 |
| Research and development expenses | 39,448 | 36,934 | 80,917 | 73,294 |
| Restructuring and impairment charges (credits) | 1,508 | (83) | 3,729 | 2,322 |
| Income from continuing operations before interest and taxes | 143,561 | 135,157 | 258,535 | 238,693 |
| Interest expense | 17,762 | 11,419 | 36,099 | 21,837 |
| Interest income | (1,156) | (229) | (1,999) | (451) |
| Income from continuing operations before taxes | 126,955 | 123,967 | 224,435 | 217,307 |
| Taxes on income from continuing operations | 15,532 | 18,412 | 35,716 | 34,385 |
| Income from continuing operations | 111,423 | 105,555 | 188,719 | 182,922 |
| Operating loss from discontinued operations | (114) | (54) | (825) | (348) |
| Tax benefit on operating loss from discontinued operations | (26) | (13) | (189) | (81) |
| Loss from discontinued operations | (88) | (41) | (636) | (267) |
| Net income | $ 111,335 | $ 105,514 | $ 188,083 | $ 182,655 |
| Basic: | ||||
| Income from continuing operations (in dollars per share) | $ 2.37 | $ 2.25 | $ 4.02 | $ 3.90 |
| Loss from discontinued operations (in dollars per share) | 0 | 0 | (0.02) | 0 |
| Net income (in dollars per share) | 2.37 | 2.25 | 4.00 | 3.90 |
| Diluted: | ||||
| Income from continuing operations (in dollars per share) | 2.35 | 2.23 | 3.99 | 3.86 |
| Loss from discontinued operations (in dollars per share) | 0 | 0 | (0.01) | 0 |
| Net income (in dollars per share) | $ 2.35 | $ 2.23 | $ 3.98 | $ 3.86 |
| Weighted average common shares outstanding | ||||
| Basic (in shares) | 46,981 | 46,901 | 46,965 | 46,889 |
| Diluted (in shares) | 47,329 | 47,347 | 47,307 | 47,374 |
TFX Balance Sheet
2023-07-02CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jul. 02, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 250,816 | $ 292,034 |
| Accounts receivable, net | 429,309 | 408,834 |
| Inventories | 631,555 | 578,507 |
| Prepaid expenses and other current assets | 120,190 | 125,084 |
| Prepaid taxes | 13,929 | 6,524 |
| Total current assets | 1,445,799 | 1,410,983 |
| Property, plant and equipment, net | 464,609 | 447,205 |
| Operating lease assets | 123,215 | 131,211 |
| Goodwill | 2,546,130 | 2,536,730 |
| Intangible assets, net | 2,227,947 | 2,306,165 |
| Deferred tax assets | 6,278 | 6,402 |
| Other assets | 81,747 | 89,367 |
| Total assets | 6,895,725 | 6,928,063 |
| Current liabilities | ||
| Current borrowings | 87,500 | 87,500 |
| Accounts payable | 142,081 | 126,807 |
| Accrued expenses | 127,861 | 140,644 |
| Payroll and benefit-related liabilities | 106,177 | 133,092 |
| Accrued interest | 5,793 | 5,332 |
| Income taxes payable | 20,184 | 24,736 |
| Other current liabilities | 65,853 | 63,381 |
| Total current liabilities | 555,449 | 581,492 |
| Long-term borrowings | 1,470,674 | 1,624,023 |
| Deferred tax liabilities | 385,113 | 388,886 |
| Pension and postretirement benefit liabilities | 30,686 | 31,394 |
| Noncurrent liability for uncertain tax positions | 6,534 | 5,805 |
| Noncurrent operating lease liabilities | 112,229 | 120,437 |
| Other liabilities | 119,948 | 154,058 |
| Total liabilities | 2,680,633 | 2,906,095 |
| Commitments and contingencies | ||
| Total shareholders' equity | 4,215,092 | 4,021,968 |
| Total liabilities and shareholders' equity | $ 6,895,725 | $ 6,928,063 |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.